Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapiesRead More
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II TrialRead More
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 studyRead More
Ibrutinib improves survival compared to chemotherapy in mantle cell lymphoma with central nervous system relapseRead More
A Randomized Phase 3 Trial of Zanubrutinib versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: THE ASPEN STUDYRead More
An International Multicenter Retrospective Analysis of Patients With Extranodal Marginal Zone Lymphoma and Histologically Confirmed Central Nervous System and Dural InvolvementRead More
Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLLRead More
COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter studyRead More
